B1 cells are unaffected by immune modulatory treatment in remitting-relapsing multiple sclerosis patients
Rovituso D, Heller S, Schroeter M, Kleinschnitz C, Kuerten S (2014)
Publication Type: Journal article
Publication year: 2014
Journal
Book Volume: 272
Pages Range: 86-90
Journal Issue: 1-2
DOI: 10.1016/j.jneuroim.2014.04.008
Abstract
In this study we aimed to investigate whether treatment with an immune modulatory drug had an effect on the distribution of B cell subpopulations in patients with remitting-relapsing multiple sclerosis (RRMS). We investigated the first-line drugs glatiramer acetate, interferon-β and natalizumab. Our data show that the frequency of the CD27+CD43+ B1 cell subset was significantly diminished in RRMS patients compared to healthy subjects and that this subset was unaffected by treatment. Regardless of their true nature, we believe that these cells are part of the autoimmune disease pattern. © 2014 Elsevier B.V.
Authors with CRIS profile
Involved external institutions
Universitätsklinikum Köln
Germany (DE)
Universitätsklinikum Würzburg
Germany (DE)
Julius-Maximilians-Universität Würzburg
Germany (DE)
Germany (DE)
Universitätsklinikum Würzburg
Germany (DE)
Julius-Maximilians-Universität Würzburg
Germany (DE)
How to cite
APA:
Rovituso, D., Heller, S., Schroeter, M., Kleinschnitz, C., & Kuerten, S. (2014). B1 cells are unaffected by immune modulatory treatment in remitting-relapsing multiple sclerosis patients. Journal of Neuroimmunology, 272(1-2), 86-90. https://doi.org/10.1016/j.jneuroim.2014.04.008
MLA:
Rovituso, Damiano, et al. "B1 cells are unaffected by immune modulatory treatment in remitting-relapsing multiple sclerosis patients." Journal of Neuroimmunology 272.1-2 (2014): 86-90.
BibTeX: Download